- Home
- NSLR vs PRQR Comparison
NSLR vs PRQR Comparison
Compare NSLR & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSLR | PRQR |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.3M | 190.5M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NSLR | PRQR |
|---|---|---|
| Price | $6.13 | $1.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $14.15 | $7.78 |
| AVG Volume (30 Days) | 284.7K | ★ 935.8K |
| Earning Date | 11-03-2026 | 11-20-2026 |
| Dividend Yield | ★ 17.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.25 |
| Revenue Next Year | $14.90 | N/A |
| P/E Ratio | $1.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.46 | $1.20 |
| 52 Week High | $12.19 | $2.49 |
Technical Indicators
Market Signals| Indicator | NSLR | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 44.22 |
| Support Level | $5.72 | $1.37 |
| Resistance Level | $8.36 | $1.54 |
| Average True Range (ATR) | 0.31 | 0.09 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 72.97 | 60.00 |
Price Performance
Historical ComparisonAbout NSLR Neostellar Capital Corp. Common Stock
Neostellar Capital Corp is an investment company focused on private, venture-backed businesses. It invests in companies that are not yet listed on a public stock exchange. It helps investors to gain exposure to a portfolio of VC-backed companies through a publicly traded stock.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.